|
|
|
|
| LEADER |
01616 am a22002533u 4500 |
| 001 |
113061 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Cohen, Daniel Tzvi
|e author
|
| 100 |
1 |
0 |
|a Cohen, Daniel Tzvi
|e contributor
|
| 100 |
1 |
0 |
|a Zhang, Chi
|e contributor
|
| 100 |
1 |
0 |
|a Pentelute, Bradley L.
|e contributor
|
| 100 |
1 |
0 |
|a Buchwald, Stephen Leffler
|e contributor
|
| 700 |
1 |
0 |
|a Zhang, Chi
|e author
|
| 700 |
1 |
0 |
|a Pentelute, Bradley L.
|e author
|
| 700 |
1 |
0 |
|a Buchwald, Stephen Leffler
|e author
|
| 245 |
0 |
0 |
|a An Umpolung Approach for the Chemoselective Arylation of Selenocysteine in Unprotected Peptides
|
| 260 |
|
|
|b American Chemical Society (ACS),
|c 2018-01-11T14:59:13Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/113061
|
| 520 |
|
|
|a Herein we report an umpolung strategy for the bioconjugation of selenocysteine in unprotected peptides. This mild and operationally simple approach takes advantage of the electrophilic character of an oxidized selenocysteine (Se-S bond) to react with a nucleophilic arylboronic acid to provide the arylated selenocysteine within hours. This reaction is amenable to a wide range of boronic acids with different biorelevant functional groups and is unique to selenocysteine. Experimental evidence indicates that under oxidative conditions the arylated derivatives are more stable than the corresponding alkylated selenocysteine.
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (Award GM46059)
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (Award GM108294)
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (Award GM110535)
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Journal of the American Chemical Society
|
